MX2024007903A - Terapia genica para deficiencias relacionadas con lamina a. - Google Patents

Terapia genica para deficiencias relacionadas con lamina a.

Info

Publication number
MX2024007903A
MX2024007903A MX2024007903A MX2024007903A MX2024007903A MX 2024007903 A MX2024007903 A MX 2024007903A MX 2024007903 A MX2024007903 A MX 2024007903A MX 2024007903 A MX2024007903 A MX 2024007903A MX 2024007903 A MX2024007903 A MX 2024007903A
Authority
MX
Mexico
Prior art keywords
aav
lamin
hlamina
raav
itr
Prior art date
Application number
MX2024007903A
Other languages
English (en)
Spanish (es)
Inventor
Christian Hinderer
Original Assignee
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania filed Critical Univ Pennsylvania
Publication of MX2024007903A publication Critical patent/MX2024007903A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0033—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being non-polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/008—Vector systems having a special element relevant for transcription cell type or tissue specific enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/15—Vector systems having a special element relevant for transcription chimeric enhancer/promoter combination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/48—Vector systems having a special element relevant for transcription regulating transport or export of RNA, e.g. RRE, PRE, WPRE, CTE
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
MX2024007903A 2021-12-24 2022-12-24 Terapia genica para deficiencias relacionadas con lamina a. MX2024007903A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163293680P 2021-12-24 2021-12-24
PCT/US2022/082383 WO2023122803A1 (en) 2021-12-24 2022-12-24 Gene therapy for lamin a - associated deficiencies

Publications (1)

Publication Number Publication Date
MX2024007903A true MX2024007903A (es) 2024-07-10

Family

ID=86903820

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024007903A MX2024007903A (es) 2021-12-24 2022-12-24 Terapia genica para deficiencias relacionadas con lamina a.

Country Status (11)

Country Link
US (1) US20250049949A1 (cg-RX-API-DMAC10.html)
EP (1) EP4453226A4 (cg-RX-API-DMAC10.html)
JP (1) JP2025501768A (cg-RX-API-DMAC10.html)
KR (1) KR20240118821A (cg-RX-API-DMAC10.html)
CN (1) CN118434877A (cg-RX-API-DMAC10.html)
AU (1) AU2022419657A1 (cg-RX-API-DMAC10.html)
CA (1) CA3241202A1 (cg-RX-API-DMAC10.html)
CO (1) CO2024008188A2 (cg-RX-API-DMAC10.html)
IL (1) IL313734A (cg-RX-API-DMAC10.html)
MX (1) MX2024007903A (cg-RX-API-DMAC10.html)
WO (1) WO2023122803A1 (cg-RX-API-DMAC10.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4634394A2 (en) 2022-12-17 2025-10-22 The Trustees of The University of Pennsylvania Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same
WO2024130070A2 (en) 2022-12-17 2024-06-20 The Trustees Of The University Of Pennsylvania Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof
WO2025007046A1 (en) 2023-06-29 2025-01-02 The Trustees Of The University Of Pennsylvania Mutant aav with central nervous system targeting motifs and compositions containing same
WO2025075551A1 (en) * 2023-10-06 2025-04-10 National University Of Singapore Method of treating lmna dilated cardiomyopathy
KR20260114566A (ko) 2023-11-14 2026-07-22 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 심근 및 골격근-특이적 표적화 모티프를 갖는 조성물 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7291699B2 (en) * 2003-03-18 2007-11-06 The Regents Of The University Of Colorado Product and methods for diagnosis and therapy for cardiac and skeletal muscle disorders
WO2013071047A1 (en) * 2011-11-11 2013-05-16 Children's Medical Center Corporation Compositions and methods for in vitro transcription of rna
US12404522B2 (en) * 2018-01-19 2025-09-02 Agency For Science, Technology And Research Disrupting the LINC complex for treating laminopathy
WO2020176896A1 (en) * 2019-02-28 2020-09-03 Encoded Therapeutics, Inc. Compositions and methods for treating laminopathies
EP4198053A1 (en) * 2021-12-15 2023-06-21 Universitätsklinikum Hamburg-Eppendorf Lmna gene expression for treatment of laminopathies

Also Published As

Publication number Publication date
WO2023122803A1 (en) 2023-06-29
US20250049949A1 (en) 2025-02-13
EP4453226A4 (en) 2026-03-18
JP2025501768A (ja) 2025-01-23
EP4453226A1 (en) 2024-10-30
CA3241202A1 (en) 2023-06-29
AU2022419657A1 (en) 2024-06-13
CO2024008188A2 (es) 2024-08-08
IL313734A (en) 2024-08-01
KR20240118821A (ko) 2024-08-05
CN118434877A (zh) 2024-08-02

Similar Documents

Publication Publication Date Title
CO2024008188A2 (es) Terapia génica para deficiencias relacionadas con lámina a
BR112021011143A2 (pt) Composições para redução específica de drg da expressão de transgene
MX2022009883A (es) Vectores de genoterapia para tratar enfermedades cardíacas.
US9012224B2 (en) Chimeric vectors
US9522182B2 (en) Prophylaxis and treatment of PRDC
MX2024000175A (es) Casetes de expresión optimizada para genoterapia.
CN101610786B (zh) 预防和治疗亚临床pcvd
WO2019169004A8 (en) Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor
EP3466442A1 (en) Treatment of mda seropositive pigs with pcv2 antigen
CL2020001428A1 (es) Terapia genética para la mucopolisacaridosis iiib.
MY199445A (en) Adeno-associated virus variant capsids and methods of use thereof
MX2023012410A (es) Metodos para tratar enfermedades oculares usando variantes de aav2 que codifican aflibercept.
RU2016105965A (ru) Вариант aav, композиции и способы, в которых он используется, а также способы его применения для переноса генов в клетки, органы и ткани
UA110632C2 (uk) Цирковірус свиней 2 типу (цвс2), імуногенна композиція, що містить його, набір для аналізу та їх застосування
WO2022229703A3 (en) New aav8 based immune escaping variants
US20230212609A1 (en) Codon-optimized nucleic acid encoding smn1 protein
MX2025003411A (es) Vectores de aav recombinantes para tratamiento de distrofia muscular
MX2024010002A (es) Metodo para reducir la fluctuacion del cst en amd neovascular mediante un virus adenoasociado recombinante
PH12022551878A1 (en) Modified adeno-associated viral capsid proteins for ocular gene therapy and methods of use thereof
BR112022003206A2 (pt) Métodos para tratar doenças neovasculares oculares usando variantes de aav2 que codificam aflibercepte
MX2022014255A (es) Composiciones utiles para el tratamiento de la enfermedad de pompe.
CN103333849A (zh) 金黄色葡萄球菌突变株及其制备方法和应用
BR112022013914A2 (pt) Composições úteis para tratar gangliosidose gm1
WO2023086928A3 (en) Gene therapy for treatment of mucopolysaccharidosis iiia
JOP20240264A1 (ar) تركيبات وطرق لعلاج ضعف السمع غير المرتبط بالعمر في خاضع للعلاج من البشر